Kotze PG

ORCID: 0000-0002-9632-6691 · 1 paper in corpus · active 2018
2018
Therapeutic advances in gastroenterology ·doi:10.1177/1756284818783614

BackgroundVedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study…